Boston Scientific Parkinson's DBS treatment wins CE mark

Boston Scientific ($BSX) gained a CE mark for its Vercise deep brain stimulation system as a Parkinson's disease treatment. It uses electrical signals on specific areas of the brain to address Parkinson's symptoms. The Natick, MA-based device company bills its system as the first on the commercial market able to use multiple independent current control. Vercise could reach an enormous amount of Parkinson's patients; as many as 6.3 million people globally, according to data Boston Scientific cites from the European Parkinson's Disease Association. Release

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.